|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-4-30
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The primary objective was to assess the safety and tolerability of pitavastatin 4mg once daily during 52 weeks treatment. The secondary objectives were to assess the effect on lipid and lipoprotein fractions and ratios, and LDL-C target attainment.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1879-1484
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
210
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
202-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20080236-Cholesterol, HDL,
pubmed-meshheading:20080236-Cholesterol, LDL,
pubmed-meshheading:20080236-Drug Tolerance,
pubmed-meshheading:20080236-Dyslipidemias,
pubmed-meshheading:20080236-Enzyme Inhibitors,
pubmed-meshheading:20080236-Female,
pubmed-meshheading:20080236-Humans,
pubmed-meshheading:20080236-Hypercholesterolemia,
pubmed-meshheading:20080236-Lipoproteins,
pubmed-meshheading:20080236-Male,
pubmed-meshheading:20080236-Middle Aged,
pubmed-meshheading:20080236-Quinolines
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia.
|
|
pubmed:affiliation |
Lipid Clinic, Rikshospitalet, Oslo University Hospital, Oslo N-0027, Norway. leiv.ose@rikshospitalet.no
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
